Compare · DFTX vs HAPP
DFTX vs HAPP
Side-by-side comparison of Definium Therapeutics Inc. (DFTX) and Happiness Development Group Limited (HAPP): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DFTX and HAPP operate in Medicinal Chemicals and Botanical Products (Health Care), so they compete in similar markets.
- DFTX is the larger of the two at $5.14B, about 344.7x HAPP ($14.9M).
- DFTX has hit the wire 7 times in the past 4 weeks while HAPP has been quiet.
- DFTX has more recent analyst coverage (7 ratings vs 0 for HAPP).
- Company
- Definium Therapeutics Inc.
- Happiness Development Group Limited
- Price
- $38.20+0.32%
- $4.52-2.80%
- Market cap
- $5.14B
- $14.9M
- 1M return
- -17.19%
- -
- 1Y return
- +290.79%
- -
- Industry
- Medicinal Chemicals and Botanical Products
- Medicinal Chemicals and Botanical Products
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2019
- News (4w)
- 7
- 0
- Recent ratings
- 7
- 0
Happiness Development Group Limited
Happiness Biotech Group Limited engages in the research, development, manufacture, and sale of nutraceutical and dietary supplement products in the People's Republic of China and internationally. The company's product category includes lucidum spore powders, cordyceps mycelia, Ejiao products, American ginseng products, other traditional Chinese herbal and animal extracts, vitamins, minerals, and amino acids. It sells its products through distributors, large-scale chain drugstores, malls, and supermarkets under the Happiness brand. Happiness Biotech Group Limited was founded in 2004 and is headquartered in Nanping, the People's Republic of China.
Latest DFTX
- Definium Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Definium Therapeutics Receives Breakthrough Therapy Designation for DT120 (lysergide) Orally Disintegrating Tablet (ODT) in Major Depressive Disorder (MDD) Following Positive Phase 3 Results
- Chief Executive Officer Barrow Robert was granted 40,000 shares and sold $721,733 worth of shares (19,023 units at $37.94) as part of a pre-agreed trading plan, increasing direct ownership by 1% to 1,494,640 units (SEC Form 4) (tax withholding)
- Definium Therapeutics Announces New Employee Inducement Grants
- Definium Therapeutics to Participate at Upcoming Investor Conferences and Events
- BofA Securities initiated coverage on Definium Therapeutics with a new price target
- Definium Therapeutics Announces New Employee Inducement Grants
- Amendment: SEC Form SCHEDULE 13G/A filed by Definium Therapeutics Inc.
- Chief Commercial Officer Wiley Matthew T. was granted 62,500 shares, increasing direct ownership by 36% to 237,133 units (SEC Form 4)
- Chief Medical Officer Karlin Daniel was granted 100,000 shares, increasing direct ownership by 20% to 603,282 units (SEC Form 4)
Latest HAPP
- SEC Form 6-K filed by Happiness Development Group Limited
- SEC Form 6-K filed by Happiness Development Group Limited
- SEC Form 6-K filed by Happiness Development Group Limited
- SEC Form EFFECT filed by Happiness Development Group Limited
- SEC Form F-3 filed by Happiness Development Group Limited
- SEC Form 6-K filed by Happiness Development Group Limited
- SEC Form SC 13G filed by Happiness Development Group Limited
- SEC Form SC 13G filed by Happiness Development Group Limited
- SEC Form 20-F/A filed by Happiness Development Group Limited (Amendment)
- SEC Form 6-K filed by Happiness Development Group Limited